Medscape February 26, 2025
In the first month of the new administration, President Trump sent a clear message: Diversity, equity, and inclusion (DEI) initiatives across the federal workforce would be terminated.
While these anti-DEI initiatives have largely targeted hiring practices, they also have scrutinized programs and guidance on increasing diversity in clinical trials. Within the first week of the new administration, the US Food and Drug Administration (FDA) webpages on promoting diversity in clinical trials went offline.
Building more inclusive clinical trials has become an increasing priority for clinical research to improve the generalizability of study results and better understand treatment efficacy across different patient populations. Given these benefits, these efforts will likely continue, said Doug Peddicord, PhD, executive director of the Association of...
Today's Sponsors
Today's Sponsor